Shetal Vyas

Shetal Vyas serves as the Senior Vice President of Commercial Strategy and Development at Ardelyx, Inc. since February 2025 and as an Independent Board Director for KJT since April 2023, providing governance and strategic oversight. Previous roles include Advisory Board Member for Aquent's Life Sciences Industry Group in 2024, General Manager for Uro-Oncology at Ferring Pharmaceuticals, where a groundbreaking gene therapy was launched, and Vice President of Marketing at Pentec Health, where significant revenue growth was achieved. Vyas has held various leadership positions, including experience at Vermillion, Inc., Myriad Genetics, and AstraZeneca, with a focus on marketing, sales, and operations across the life sciences field. Academic qualifications include an MBA in Marketing from Saint Joseph's University and advanced management programs from Harvard Business School.